WO2007097358A1 - Hla-a*3303拘束性wt1ペプチド、およびそれを含む医薬組成物 - Google Patents
Hla-a*3303拘束性wt1ペプチド、およびそれを含む医薬組成物 Download PDFInfo
- Publication number
- WO2007097358A1 WO2007097358A1 PCT/JP2007/053176 JP2007053176W WO2007097358A1 WO 2007097358 A1 WO2007097358 A1 WO 2007097358A1 JP 2007053176 W JP2007053176 W JP 2007053176W WO 2007097358 A1 WO2007097358 A1 WO 2007097358A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- hla
- amino acid
- cells
- pharmaceutical composition
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 139
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 35
- 108700020467 WT1 Proteins 0.000 claims abstract description 161
- 102000040856 WT1 Human genes 0.000 claims abstract description 160
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 27
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 27
- 239000002157 polynucleotide Substances 0.000 claims abstract description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 8
- 101150084041 WT1 gene Proteins 0.000 claims description 168
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 87
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 87
- 150000001413 amino acids Chemical class 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 50
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 34
- 201000011510 cancer Diseases 0.000 claims description 32
- 230000001939 inductive effect Effects 0.000 claims description 16
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 15
- 239000013604 expression vector Substances 0.000 claims description 14
- JLWZLIQRYCTYBD-IHRRRGAJSA-N Leu-Lys-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JLWZLIQRYCTYBD-IHRRRGAJSA-N 0.000 claims description 9
- VBKBDLMWICBSCY-IMJSIDKUSA-N Ser-Asp Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O VBKBDLMWICBSCY-IMJSIDKUSA-N 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- ADJWHHZETYAAAX-SRVKXCTJSA-N Leu-Ser-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N ADJWHHZETYAAAX-SRVKXCTJSA-N 0.000 claims description 3
- LECIJRIRMVOFMH-ULQDDVLXSA-N Lys-Pro-Phe Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 LECIJRIRMVOFMH-ULQDDVLXSA-N 0.000 claims description 3
- BKIFWLQFOOKUCA-DCAQKATOSA-N Met-His-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)O)N BKIFWLQFOOKUCA-DCAQKATOSA-N 0.000 claims description 3
- WEDZFLRYSIDIRX-IHRRRGAJSA-N Phe-Ser-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 WEDZFLRYSIDIRX-IHRRRGAJSA-N 0.000 claims description 3
- BLPYXIXXCFVIIF-FXQIFTODSA-N Ser-Cys-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N)CN=C(N)N BLPYXIXXCFVIIF-FXQIFTODSA-N 0.000 claims description 3
- XHWCDRUPDNSDAZ-XKBZYTNZSA-N Thr-Ser-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O XHWCDRUPDNSDAZ-XKBZYTNZSA-N 0.000 claims description 3
- 108010051242 phenylalanylserine Proteins 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 description 61
- 230000001472 cytotoxic effect Effects 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 9
- 239000007787 solid Substances 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 102000043129 MHC class I family Human genes 0.000 description 7
- 108091054437 MHC class I family Proteins 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 201000005787 hematologic cancer Diseases 0.000 description 7
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 7
- 230000006698 induction Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010005003 Bladder cancer Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 208000000453 Skin Neoplasms Diseases 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 201000000849 skin cancer Diseases 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- 206010046766 uterine cancer Diseases 0.000 description 4
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000000254 damaging effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 201000003115 germ cell cancer Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241000239290 Araneae Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100103014 Homo sapiens WT1 gene Proteins 0.000 description 1
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 description 1
- 101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 102000046004 human WT1 Human genes 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Definitions
- the present invention relates to an HLA-A * 3303-restricted WT1 peptide, specifically, a peptide comprising an amino acid sequence consisting of nine consecutive amino acids derived from the WT1 protein, the nine consecutive amino acids.
- the second amino acid in the amino acid sequence that is also a force is selected from the group forces Ala, Ile, Leu, Val, Ph e, Tyr, Ser, and Asp, and the ninth amino acid is Ar g. Relates to peptides.
- the present invention relates to a polynucleotide encoding the peptide, a pharmaceutical composition for preventing cancer treatment Z comprising the same, and the like.
- the WT1 gene (Wilms' tumor 1 gene) has been identified as a responsible gene for Wilms tumor, a childhood renal cancer (Non-patent Documents 1 and 2), and a transcription factor having a zinc finger structure. It is. Initially, the WT1 gene was considered to be a tumor suppressor gene, but subsequent studies (Non-Patent Documents 3, 4, 5 and 6) have shown that it functions as an oncogene in hematopoietic tumors and solid tumors. It was.
- mice immunized with the WT1 peptide or WT1 cDNA reject the transplanted WT1 gene-expressing tumor cells with a high probability (Non-patent Documents 7 and 10), but the WT1 gene is expressed physiologically. It was also shown that normal tissues were not damaged by induced CTL (Non-patent Document 7).
- HLA—A * 0201 high binding Dbl26 peptide and WH 187 peptide (amino acids 187-195 in SEQ ID NO: 1, SLGEQQYSV)
- HLA—A * 0201 high binding Dbl26 peptide and WH 187 peptide (amino acids 187-195 in SEQ ID NO: 1, SLGEQQYSV)
- WTl-specific CTLs that are specific injuries to tumor cells that are endogenously highly expressing the WT1 gene It has been shown that the activity and the damaging activity of CTL are HLA-A2 restricted (Non-patent Document 11).
- HLA—A reels the most common HL A—A * 2402 WT1 peptide (WT1; amino acid 235 in SEQ ID NO: 1)
- Non-patent Document 12 WT1-specific CTL
- TAK-1 WT1-specific CTL
- the WT1 gene product exists as a nuclear protein, is processed by the proteasome in the cytoplasm, and is fragmented into peptides. Fragmented peptides are displayed on the cell surface, forming a complex with the MHC class I molecule, TAP (transporter associated with antigen processing) force, forceful into the body cavity of the child / J cyst.
- TAP transporter associated with antigen processing
- the CTL progenitor cells recognize WT1 peptide MHC class I molecular complexes via TCR, leading to WT1-specific CTLs, and to tumor cells that present WT1 gene products via MHC class I molecules It exerts a cytotoxic effect (Non-patent Documents 7, 8 and 9).
- the WT1 peptide used in cancer immunotherapy targeting the WT1 gene product must be in a form that binds to MHC class I molecules at least in vivo.
- MHC class I molecules are diverse and the amino acid sequences of WT1 peptides that bind to each MHC class I molecule are different, it is necessary to prepare peptides that are suitable for each type of MHC class I.
- the only known HLA molecule-restricted WT1 peptides are HLA-A * 2402 molecule, HLA-A * 0201 molecule, and HLA-A * 2601 molecule-restricted (Patent Document 1, respectively).
- Non-patent document 11 and Patent document 2 To Japanese people! Next to HLA—A * 2402, there are many! HLA—A reel is HLA—A * 3303 Therefore, it was necessary to find HLA-A * 3303-restricted WT1 peptide.
- Patent Document 1 International Publication No. 2003Z106682
- Patent Document 2 International Publication No. 2005Z095598
- Non-Patent Literature l Daniel A. Haber et al., Cell. 1990 Jun 29; 61 (7): 1257-69.
- Non-Patent Document 2 Call KM et al., Cell. 1990 Feb 9; 60 (3): 509-20.
- Non-Patent Document 3 Menke AL et al, Int Rev Cytol. 1998; 181: 151-212. Review.
- Non-Patent Document 4 Yamagami T et al., Blood. 1996 Apr l; 87 (7): 2878-84.
- Non-Patent Document 5 Inoue K et al., Blood. 1998 Apr 15; 91 (8): 2969-76.
- Non-Patent Document 6 Tsuboi A et al., Leuk Res. 1999 May; 23 (5): 499-505.
- Non-Patent Document 7 Oka Y et al., J Immunol. 2000 Feb 15; 164 (4): 1873-80.
- Non-Patent Document 8 Melief CJ et al., Immunol Rev. 1995 Jun; 145: 167-77.
- Non-Patent Document 9 Ritz J, J Clin Oncol. 1994 Feb; 12 (2): 237-8.
- Non-Patent Document 10 Tsuboi A et al., J Clin Immunol. 2000 May; 20 (3): 195-202.
- Non-Patent Document 11 Oka Y et al., Immunogenetics. 2000 Feb; 51 (2): 99—107.
- Non-Patent Document 12 Ohminami H et al., Blood. 2000 Jan 1; 95 (1): 286-93.
- Non-Patent Document 13 Gao L et al., Blood. 2000 Apr 1; 95 (7): 2198-203.
- Non-Patent Document 14 Ohminami H et al., Blood. 2000 Jan 1; 95 (1): 286-93.
- the problem to be solved by the present invention is to provide an HLA-A * 3303-restricted WT1 peptide, a polynucleotide encoding the same, and a pharmaceutical composition for treating cancer Z containing the same, and the like.
- the present inventor is a peptide containing an amino acid sequence having nine consecutive amino acid strengths derived from the WT1 protein, the amino acid comprising the nine consecutive amino acids.
- a group force is selected in which the second amino acid in the sequence is Ala, Ile, Leu, Val, Phe, Tyr, Ser, and Asp, and the peptide in which the ninth amino acid is Arg is WT1.
- a pharmaceutical composition for treating or preventing cancer comprising the peptide according to (1),
- a method for treating or preventing cancer comprising administering an effective amount of the pharmaceutical composition according to (4) to an HLA-A * 3303-positive subject,
- a pharmaceutical composition for treating or preventing cancer comprising the polynucleotide according to (7) or the vector according to (8),
- a method for treating or preventing cancer which comprises administering an effective amount of the pharmaceutical composition according to (9) to an HLA-A * 3303-positive subject,
- Peripheral blood mononuclear cells are cultured in the presence of the peptide according to (1), from the peripheral blood mononuclear cells WT1-specific CTL induction method, characterized by inducing WT1-specific CTL,
- An antigen presenting a WT1 peptide characterized by culturing immature antigen-presenting cells in the presence of the peptide according to (1), and inducing antigen-presenting cells that present the WT1 peptide from the immature antigen-presenting cells.
- a method for inducing a presentation cell characterized by culturing immature antigen-presenting cells in the presence of the peptide according to (1), and inducing antigen-presenting cells that present the WT1 peptide from the immature antigen-presenting cells.
- kits for inducing an antigen-presenting cell that presents a WT1 peptide comprising the peptide according to (1) as an essential component;
- a method for determining the presence or amount of WT1-specific CTL in an HLA-A * 3303 positive subject comprising:
- an HLA-A * 3303-restricted WT1 peptide, a polynucleotide encoding the same, and a cancer treatment containing the same, and a pharmaceutical composition for preventing Z can be obtained.
- In vivo and in vitro induction of WT1-specific CTLs is possible.
- About 24% of Japanese have at least one HLA-A * 3303 molecule, which can induce WT1-specific CTL in a very wide range of subjects.
- FIG. 1 shows the cytotoxic activity of CTL induced with WT1.
- FIG. 2 shows the cytotoxic activity of CTL induced with WT1.
- FIG. 3 shows the cytotoxic activity of CTL induced with WT1.
- FIG. 4 shows the cytotoxic activity of CTL induced with WT1.
- Fig. 5 shows a comparison of CTL-induced endogenous WT1 gene-expressing cells with WT1.
- Fig. 6 shows the expression of CTL induced by WT1 against endogenous WT1 gene-expressing cells.
- FIG. 7 shows that CTLs induced with WT1 were compared with cells expressing endogenous WT1 gene.
- Fig. 8 shows the details of CTL induced by WT1 against cells expressing WT1 gene.
- WT1 gene is, for example, leukemia, myelodysplastic syndrome, multiple myeloma, malignant lymphoma and other hematopoietic tumors, stomach cancer, colon cancer, lung cancer, breast cancer, germ cell cancer, liver cancer, skin cancer, bladder cancer, prostate cancer, It is highly expressed in natural types in solid cancers such as uterine cancer, cervical cancer and ovarian cancer.
- the HLA-A * 33 03 anchor motif has Ala, Ile, Leu, Val, Phe, Tyr, Ser, and Asp at the second position, and Arg at the ninth position.
- the present invention in one embodiment, is a peptide comprising 9 consecutive amino acid power amino acid sequences derived from the WT1 protein, which is the second position of the 9 consecutive amino acid power amino acid sequences.
- Amino acid power preferably selected from the group consisting of A1a, Ile, Leu, Val, Phe, Tyr, Ser, and Asp, and the 9th amino acid power, preferably Arg, HLA—A * 3303 Sex WT1 peptide (hereinafter also referred to as WT1 peptide).
- the nine amino acid sequences comprised by the peptide of the present invention preferred are Leu Ser His Leu Gin Met His Ser Arg (SEQ ID NO: 2), Phe Ser Arg Ser Asp Gin Leu Lys Arg ( SEQ ID NO: 3), Ser Asp Gin Leu Lys Arg His Gin Arg (SEQ ID NO: 4), or Thr Ser Glu Lys Pro Phe Ser Cys Arg (SEQ ID NO: 5), and most preferred is Ser Asp Gin Leu Lys Arg His Gin Arg (SEQ ID NO: 4).
- Ser Asp Gin Leu Lys Arg His Gin Arg SEQ ID NO: 4
- any of SEQ ID NOs: 2 to 5 even if one to several, preferably 1 to 5 amino acids of the 9 amino acids are substituted with another amino acid Good.
- any of the nine amino acids and other substituted amino acids may be appropriately modified. However, in any case, it is a condition that the peptide of the present invention retains the binding ability to the HLA-A * 3303 molecule.
- the object of the present invention is to obtain a WT1 peptide having HLA-A * 3303 restriction as described above. Therefore, the peptide of the present invention is derived from WT1 protein,
- the peptide of the present invention may be the peptide itself consisting of the amino acid sequences shown in SEQ ID NOs: 2 to 5 or the WT1 protein or a part thereof including the amino acid sequences shown in SEQ ID NOs: 2 to 5. May be.
- the peptide of the present invention can also bind various substances to the N-terminus and Z- or C-terminus of the amino acid sequence having nine consecutive amino acid forces. For example, amino acids, peptides, analogs thereof and the like may be bound.
- these substances are bound to the peptide of the present invention, these substances are treated with, for example, in vivo enzymes or by a process such as intracellular processing, and finally the amino acids having the above nine amino acid strengths.
- these substances may be those that regulate the solubility of the peptides of the present invention or may improve their stability, such as protease resistance.
- the peptide of the present invention may be delivered, or it may have an action of enhancing the uptake efficiency of antigen-presenting cells.
- These substances may also be those that increase the ability to induce CTL, such as helper peptides.
- the peptide of the present invention can be synthesized using a method usually used in the art or a modification thereof. For example, Peptide Synthesis, Interscience, New York, 1966; The Proteins, Vol 2, Academic Press Inc., New York, 1976; Peptide synthesis, Maruzen Co., Ltd., 1975; Fundamentals and experiments of peptide synthesis, Maruzen Co., Ltd., 1985; Drug development continued 14th 'Peptide synthesis, Hirokawa Shoten, 1991, etc.
- the peptide of the present invention can also be produced using genetic engineering techniques based on the nucleotide sequence information encoding the peptide of the present invention. Such genetic engineering techniques are well known to those skilled in the art.
- the present invention relates to a pharmaceutical composition for treating or preventing cancer, comprising the HLA-A * 3303 restricted WT1 peptide.
- WT1 gene is, for example, hematopoietic tumors such as leukemia, myelodysplastic syndrome, multiple myeloma, malignant lymphoma, stomach cancer, colon cancer, lung cancer, breast cancer, germ cell cancer, liver cancer, skin cancer, bladder cancer, prostate cancer, Since it is highly expressed in solid cancers such as uterine cancer, cervical cancer and ovarian cancer, the pharmaceutical composition of the present invention can be used for the treatment or prevention of cancer.
- the WT1-specific CTL is induced by the HLA-A * 3 303-restricted WT1 peptide contained in the pharmaceutical composition, and is profitable. CTLs damage the cancer cells in the target.
- the pharmaceutical composition of the present invention may contain, for example, a carrier, an excipient and the like in addition to the above-mentioned HLA-A * 3303 restricted WT1 peptide as an active ingredient. Since the HLA-A * 3303-restricted WT1 peptide contained in the pharmaceutical composition of the present invention induces WT1-specific CTL, the pharmaceutical composition of the present invention is suitable for increasing the induction efficiency. Or may be administered with a suitable adjuvant.
- Preferred adjuvants include, but are not limited to, complete or incomplete Freund's adjuvant, aluminum hydroxide, and the like.
- the administration method of the pharmaceutical composition of the present invention can be appropriately selected according to conditions such as the type of disease, the state of the subject, the target site and the like.
- Examples of the method include, but are not limited to, intradermal administration, subcutaneous administration, intramuscular administration, intravenous administration, nasal administration, and oral administration.
- the amount of peptide contained in the pharmaceutical composition of the present invention, the dosage form of the pharmaceutical composition, the number of administrations, etc. can be appropriately selected according to conditions such as the type of disease, the condition of the subject, the target site, etc.
- Peptide dosage is usually 0. OOOlmg: LOOOmg, preferably ⁇ 0.00 lmg ⁇ : LOOOOmg.
- the present invention relates to a method for treating or preventing cancer, which comprises administering an effective amount of the above pharmaceutical composition to an HLA-A * 3303-positive subject.
- the cancer to be treated or prevented may be any of, for example, hematopoietic tumors such as leukemia, myelodysplastic syndrome, multiple myeloma, malignant lymphoma, stomach cancer, colon cancer, lung cancer, breast cancer, germ cell Including solid cancers such as cancer, liver cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical cancer, and oval cancer.
- the present invention relates to the use of HLA-A * 3303-restricted WT1 peptide for producing the above pharmaceutical composition.
- the present invention provides a method for determining the presence or amount of WT1-specific CTL in an HLA-A * 3303-positive subject comprising:
- the present invention relates to a method comprising the step of examining the presence or amount of CTL that recognizes the complex contained in the sample.
- the subject-derived sample may be any sample that may contain lymphocytes. Examples thereof include body fluids such as blood and lymph, and tissues.
- the complex of the WT1 peptide and the HLA-A * 3303 molecule may be in the form of, for example, a tetramer or a pentamer using a method known to those skilled in the art, such as the biotin streptavidin method. .
- the presence or amount of CTL that recognizes a strong complex can be measured by methods known to those skilled in the art.
- the complex may be labeled.
- label known ones such as a fluorescent label and a radioactive label can be used. Labeling makes it easier and faster to determine the presence or amount of CTL. Using the method of this aspect of the present invention, cancer diagnosis, prognosis, and the like are possible.
- the present invention also provides a composition comprising a complex of a WT1 peptide and an HLA-A * 3303 molecule for determining the presence or amount of WT1-specific CTL in an HLA-A * 3303 positive subject I will provide a.
- the present invention provides an HLA comprising a complex of a WT1 peptide and an HLA-A * 3303 molecule.
- the present invention provides a method for obtaining WT1-specific CTL using a complex of a WT1 peptide and an HLA-A * 3303 molecule,
- the present invention relates to a method including steps.
- the complex of WT1 peptide and HLA-A * 3303 molecule is as described above.
- the sample may be any sample as long as it may contain lymphocytes. Examples thereof include a subject-derived sample such as blood and a cell culture solution. Acquisition of CTL that recognizes the complex can be performed using methods known to those skilled in the art, such as FACS and MACS.
- the obtained WT1-specific CTL can be cultured and used for treatment or prevention of various cancers.
- the present invention also relates to a WT1-specific CTL that can be obtained by a method for obtaining a WT1-specific CTL using a complex of a WT1 peptide and an HLA-A * 3303 molecule.
- the present invention relates to a kit for obtaining a WT1-specific CTL comprising a complex of a WT1 peptide and an HLA-A * 3303 molecule.
- the present invention relates to a polynucleotide encoding the above-mentioned HLA-A * 3303 restricted WT1 peptide (hereinafter also referred to as WT1 polynucleotide).
- the polynucleotide of the present invention may be DNA or RNA.
- the nucleotide sequence of the polynucleotide of the present invention can be determined based on the amino acid sequence of the HLA-A * 3303 restricted WT1 peptide.
- the polynucleotide can be produced, for example, by a DNA or RNA synthesis method, a PCR method or the like.
- the present invention relates to an expression vector (hereinafter also referred to as a WT 1 expression vector) comprising the above polynucleotide.
- the type of expression vector, sequences contained other than the above-described polynucleotide sequences, and the like can be appropriately selected according to the type, purpose, etc. of the host into which the expression vector is introduced.
- the expression vector of the present invention is administered to an HLA-A * 3303 positive subject to produce a WT1 peptide in vivo and induce WT1-specific CTL.
- the present invention relates to a pharmaceutical composition for treating or preventing cancer, comprising the WT1 polynucleotide or the WT1 expression vector.
- a pharmaceutical composition for treating or preventing cancer comprising the WT1 polynucleotide or the WT1 expression vector.
- the composition, administration method and the like of the pharmaceutical composition of this aspect of the present invention are as described above.
- the present invention provides a therapeutic or cancer treatment, characterized in that a pharmaceutical composition comprising an effective amount of the above WT1 polynucleotide or WT1 expression vector is administered to an HLA-A * 3303-positive subject. It relates to a method for prevention.
- Cancers to be treated or prevented include hematopoietic tumors such as leukemia, myelodysplastic syndrome, multiple myeloma, malignant lymphoma, stomach cancer, colon cancer, lung cancer, breast cancer, germ cell cancer, liver cancer, skin cancer, bladder cancer, Includes solid cancers such as prostate cancer, uterine cancer, cervical cancer and ovarian cancer.
- the present invention relates to the use of a WT1 polynucleotide or WT1 expression vector for producing a pharmaceutical composition comprising the WT1 polynucleotide or WT1 expression vector.
- the present invention relates to a cell containing the WT1 expression vector.
- the cells of the present invention can be produced, for example, by transforming host cells such as Escherichia coli, yeast, insect cells, and animal cells using the expression vector.
- As a method for introducing an expression vector into a host cell various methods can be appropriately selected and used.
- the peptide of the present invention can also be produced by culturing transformed cells and recovering and purifying the produced WT1 peptide.
- the present invention relates to a WT1-specific CTL induced by the HLA-A * 3303 restricted WT1 peptide.
- the CTL of the present invention recognizes a complex of WT1 peptide and HLA-A * 3303 molecule. Therefore, using the CTL of the present invention, HLA-A * 3303-positive and WT1-highly expressing tumor cells can be specifically damaged.
- the present invention relates to a method for treating or preventing cancer, which comprises administering WT1-specific CTL to an HLA-A * 3303-positive subject.
- the WT1-specific CTL administration method depends on conditions such as the type of disease, the condition of the subject, and the target site. It can be selected as appropriate according to the conditions. Examples of the method include, but are not limited to, intravenous administration, intradermal administration, subcutaneous administration, intramuscular administration, nasal administration, and oral administration.
- the present invention provides a method in which peripheral blood mononuclear cells are cultured in the presence of the above-mentioned HLA-A * 3303-restricted WT 1 peptide.
- the present invention relates to a method for inducing WT1-specific CTL characterized by induction.
- the subject from which the peripheral blood mononuclear cells are derived may be any as long as it is HLA-A * 3303 positive.
- WT1-specific CTLs are induced from CTL progenitor cells in peripheral blood mononuclear cells.
- WT1-specific CTL obtained by the present invention to HLA-A * 3303-positive subjects, hematopoietic tumors and solid cancers in the subjects can be treated or prevented.
- the present invention relates to a kit for inducing WT1-specific CTL comprising HLA-A * 3303-restricted WT1 peptide as an essential component.
- the kit is used in the above-described method for inducing WT1-specific CTL.
- the kit of the present invention may contain, for example, means for obtaining peripheral blood mononuclear cells, an adjuvant, a reaction container, and the like.
- an instruction manual is attached to the kit. WT1-specific CTL can be efficiently induced using the kit of the present invention.
- the present invention provides an antigen-presenting cell (spider cell) that presents the WT1 peptide via the HLA-A * 3303 molecule, which is induced by the HLA-A * 3303-restricted WT1 peptide. Etc.).
- an antigen-presenting cell spike cell
- the WT1-specific CTL is efficiently induced.
- the present invention provides a method for treating cancer, characterized in that antigen-presenting cells that present the WT1 peptide via HLA-A * 3303 molecules are administered to HLA-A * 3303-positive subjects. Or it relates to a method for prevention.
- the administration method of antigen-presenting cells can be appropriately selected according to conditions such as the type of disease, the state of the subject, and the target site. Examples of the method include, but are not limited to, intravenous administration, intradermal administration, subcutaneous administration, intramuscular administration, nasal administration, and oral administration.
- immature antigen-presenting cells are cultured in the presence of the above-mentioned HLA-A * 3303-restricted WT1 peptide, and WT1 peptide is converted from the immature antigen-presenting cells to HLA-A * 3303 molecules.
- the present invention relates to a method for inducing an antigen-presenting cell that presents a WT1 peptide via an HLA-A * 3303 molecule.
- An immature antigen-presenting cell refers to a cell that can mature to become an antigen-presenting cell, such as an immature rod-shaped cell.
- the subject from which immature antigen-presenting cells are derived may be any subject as long as it is HLA-A * 3303-positive. Since immature antigen-presenting cells are contained in, for example, peripheral blood mononuclear cells, vigorous cells may be cultured in the presence of the WT1 peptide.
- the present invention induces antigen-presenting cells that contain the above-mentioned HLA-A * 3303-restricted WT1 peptide as an essential component and present the WT1 peptide via an HLA-A * 3303 molecule.
- the kit is used for the method for inducing antigen-presenting cells.
- Other components included in the kit of the present invention are as described above. Using the kit of the present invention, antigen-presenting cells that present the WT1 peptide via HLA-A * 3303 molecules can be efficiently induced.
- the present invention relates to an antibody against an HLA-A * 3303 restricted WT1 peptide or an antibody against a polynucleotide encoding the peptide.
- the antibody of the present invention may be either a polyclonal antibody or a monoclonal antibody
- the present invention provides an WT1-specific CTL, an antigen-presenting cell that presents the WT1 peptide via an HLA-A * 3303 molecule, or an antibody against an HLA-A * 3303-restricted WT1 peptide
- the present invention relates to a method for diagnosing cancer, which comprises using an antibody against a polynucleotide encoding a peptide.
- WT1-specific CTL is used in the diagnostic method of the present invention.
- the CTL, antigen-presenting cell or antibody is incubated with a sample from an HLA-A * 3303-positive subject or administered to an HLA-A * 3303-positive subject, and then the CTL, antigen-presenting cell or For example, cancer can be diagnosed by determining the position, site, amount, etc. of the antibody.
- the CTL, antigen-presenting cell or antibody may be labeled. By attaching a powerful sign Thus, the diagnostic method of the present invention can be performed efficiently.
- the present invention provides an WT1-specific CTL, an antigen-presenting cell that presents the WTl peptide via an HLA-A * 3303 molecule, an antibody against an HLA-A * 3303-restricted WT1 peptide,
- the present invention relates to a cancer diagnostic kit comprising an antibody against a polynucleotide encoding a peptide as an essential component.
- the HLA-A * 3303 compatible anchor motif (the second amino acid from the N-terminus is Ala, Ile, A 9-amino-acid hydrophilic peptide with Leu, Val, Phe, Tyr, Ser, or Asp (Cg-terminal is Arg), and has a binding affinity for the HLA-A * 3303 molecule Peptides WTl and WT which are estimated to be high
- Table 1 shows the binding affinity for A * 3303 molecules.
- Peripheral blood power collected from HLA-A * 3303 positive healthy donors HLA-A * 3303/0207
- Peripheral blood mononuclear cells PBM C
- PBMC in a 24-well cell culture plate containing 10% FCS RP Seed at a density of about 1 x 10 7 cells in MI 1640 medium, add culture supernatant of B95-8 cells (EB virus producing cells), and culture at 37 ° C, 5% CO for about 1 month did. Due to EB virus
- B-LCL cells B-cell lineage tumor cells, were obtained. It was confirmed that the obtained B-LCL cells did not express the WT1 gene.
- B—LCL cells can be incubated with gZml WT1, WT1, WT1 or WT1 for 2 hours.
- B-LCL cells pulsed with WT1 peptide were used as antigen-presenting cells in the following experiments.
- PBMC HLA—A * 3303/1101
- responder cells were obtained.
- the obtained 2 ⁇ 10 6 responding cells were co-cultured with 1 ⁇ 10 6 B-LCL cells that had been nor- malized with the same WT1 peptide for 1 week in the complete medium (first stimulation).
- PBMC were co-cultured with B—LCL cells pulsed with WT1 peptide three more times (2-4 stimulation), with 20 IUZml (final concentration) IL-2 under the following conditions;
- 2nd stimulation After 3 days, a total of 2 times a day; 3rd and 4th stimulation: The next day after the start of stimulation, a total of 3 times a day was applied.
- the obtained cells were concentrated using a Negative Selection Columns Gravity Feed Kit (StemSp) so that the CD8 positive T cells were about 80%, and then co-cultured with B-LCL cells pulsed with WT1 peptide ( 5th stimulation).
- CD8 positive T cells (CTL) 5 days after the start of stimulation were used for the measurement of cytotoxic activity.
- CTL cells (hereinafter also referred to as single effector cells) are mixed with the target cells that have been intensively incorporated with 51 Cr in a ratio of 1: 1, 5: 1, or 10: 1 (EZT ratio). Prepared to 200 ⁇ l and cultured in a 96-well cell culture plate at 37 ° C, 5% CO for 4 hours. WT1 used for CTL induction as target cell
- B-LCL cells (BLCL-P) pulsed with the same peptide as the peptide and B-LCL cells (BLCL-NP) not pulsed with WT1 peptide were used. After incubation, centrifuge The supernatant was collected and the amount of 51 Cr released in the supernatant was measured using a liquid scintillation counter. Cytotoxic activity (%) in the following formula:
- TF-1 cells Cytotoxic activity against tumor cells TF-1 cells (HLA-A * 3303 positive) was determined using the method described above.
- K562 cells which are HLA-A * 3303-negative cells expressing the WT1 gene, were used. The results are shown in Figs. In the figure, the vertical axis indicates specific lysis (%), and the horizontal axis indicates the EZT ratio.
- TF-1 is indicated by a solid line and K562 is indicated by a dotted line.
- CTL force induced by WT1, WT1 and WTl WTl gene is endogenous
- WT1-expressing B- LCL cells are B- LCL cells into which the human WT1 gene has been introduced, which expresses the WT1 protein in the cell and is processed to produce a peptide with about 9 amino acid strength. Refers to a cell that presents with the HLA-A * 3303 molecule.
- B-LCL cells B-LCL-CV
- FIG. 1 the vertical axis shows specific lysis (%), and the horizontal axis shows the EZT ratio.
- B—LCL—WT1 , B—LCL—CV is indicated by a dotted line.
- CTL induced with WT1 is HLA-A * 3
- a WT1 peptide restricted by HLA-A * 3303 a polynucleotide encoding the peptide, a pharmaceutical composition containing the same, and the like are provided. Therefore, in the field of pharmaceuticals, for example, the WT1 gene is highly expressed. It can be used in the development and manufacturing fields of various hematopoietic tumors, solid cancer preventives or therapeutics.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Description
Claims
Priority Applications (24)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0708125-1A BRPI0708125A2 (pt) | 2006-02-22 | 2007-02-21 | peptìdio restrito á hla-a*3303 da wt1 e composição farmacêutica compreendendo o mesmo |
MX2008010842A MX2008010842A (es) | 2006-02-22 | 2007-02-21 | Peptido de tumor de wilms restringido por antigeno leucocitario humano-a*3303 y composicion farmaceutica que comprenden el mismo. |
JP2008501735A JP5393144B2 (ja) | 2006-02-22 | 2007-02-21 | Hla−a*3303拘束性wt1ペプチド、およびそれを含む医薬組成物 |
EP07714676A EP1988163B1 (en) | 2006-02-22 | 2007-02-21 | Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same |
SI200730972T SI1988163T1 (sl) | 2006-02-22 | 2007-02-21 | HLA-A*3303-omejen WT1 peptid in farmacevtski sestavek, ki ga vsebuje |
CA002638122A CA2638122A1 (en) | 2006-02-22 | 2007-02-21 | Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same |
US12/280,268 US8759483B2 (en) | 2006-02-22 | 2007-02-21 | HLA-A* 3303-restricted WT1 peptide and pharmaceutical composition comprising the same |
PL07714676T PL1988163T3 (pl) | 2006-02-22 | 2007-02-21 | Ograniczony do hla-a*3303 peptyd wt1 i zawierająca go kompozycja farmaceutyczna |
ES07714676T ES2387685T3 (es) | 2006-02-22 | 2007-02-21 | Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo |
AU2007218649A AU2007218649B2 (en) | 2006-02-22 | 2007-02-21 | HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same |
CN2007800059709A CN101384716B (zh) | 2006-02-22 | 2007-02-21 | Hla-a*3303限制性wt1肽和包含此肽的药物组合物 |
DK07714676.9T DK1988163T3 (da) | 2006-02-22 | 2007-02-21 | Hla-a*3303-begrænset wt1 peptid og farmaceutisk sammensætning omfattende det samme |
IL193026A IL193026A (en) | 2006-02-22 | 2008-07-24 | 3303 * a – hla –peptide 1wt peptide and a pharmaceutical preparation containing it |
KR1020087020447A KR101391561B1 (ko) | 2006-02-22 | 2008-08-21 | Hla-a*3303 구속성 wt1 펩티드, 및 그것을 포함하는 의약 조성물 |
NO20084008A NO20084008L (no) | 2006-02-22 | 2008-09-19 | HLA-A 3303-begrenset WT1-peptid og farmasoytisk preparat omfattende det samme |
HK09103920.0A HK1125968A1 (ja) | 2006-02-22 | 2009-04-28 | |
IL218172A IL218172A0 (en) | 2006-02-22 | 2012-02-16 | Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same |
US13/411,453 US8778350B2 (en) | 2006-02-22 | 2012-03-02 | Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same |
PH12012502372A PH12012502372A1 (en) | 2006-02-22 | 2012-11-29 | Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same |
US14/145,363 US8945578B2 (en) | 2006-02-22 | 2013-12-31 | Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same |
US14/145,221 US8933038B2 (en) | 2006-02-22 | 2013-12-31 | Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same |
US14/145,144 US8968745B2 (en) | 2006-02-22 | 2013-12-31 | Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same |
IL232408A IL232408A0 (en) | 2006-02-22 | 2014-05-01 | 3303 * a-hla – reduced 1wt peptide and pharmaceutical compound containing it |
IL232409A IL232409A0 (en) | 2006-02-22 | 2014-05-01 | 3033*a-hla- reduced 1wt peptide and pharmaceutical compound containing it |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-045287 | 2006-02-22 | ||
JP2006045287 | 2006-02-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/280,268 A-371-Of-International US8759483B2 (en) | 2006-02-22 | 2007-02-21 | HLA-A* 3303-restricted WT1 peptide and pharmaceutical composition comprising the same |
US13/411,453 Division US8778350B2 (en) | 2006-02-22 | 2012-03-02 | Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007097358A1 true WO2007097358A1 (ja) | 2007-08-30 |
Family
ID=38437397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/053176 WO2007097358A1 (ja) | 2006-02-22 | 2007-02-21 | Hla-a*3303拘束性wt1ペプチド、およびそれを含む医薬組成物 |
Country Status (23)
Country | Link |
---|---|
US (5) | US8759483B2 (ja) |
EP (3) | EP2385117B1 (ja) |
JP (1) | JP5393144B2 (ja) |
KR (1) | KR101391561B1 (ja) |
CN (3) | CN102250211A (ja) |
AU (1) | AU2007218649B2 (ja) |
BR (1) | BRPI0708125A2 (ja) |
CA (4) | CA2886615A1 (ja) |
CY (1) | CY1113117T1 (ja) |
DK (2) | DK1988163T3 (ja) |
ES (3) | ES2558330T3 (ja) |
HK (1) | HK1125968A1 (ja) |
IL (4) | IL193026A (ja) |
MX (1) | MX2008010842A (ja) |
MY (1) | MY149527A (ja) |
NO (1) | NO20084008L (ja) |
PH (1) | PH12012502372A1 (ja) |
PL (1) | PL1988163T3 (ja) |
PT (1) | PT1988163E (ja) |
RU (2) | RU2435782C2 (ja) |
SI (1) | SI1988163T1 (ja) |
WO (1) | WO2007097358A1 (ja) |
ZA (1) | ZA200806542B (ja) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008105462A1 (ja) | 2007-02-27 | 2008-09-04 | International Institute Of Cancer Immunology, Inc. | ヘルパーt細胞の活性化方法およびそのための組成物 |
WO2012046730A1 (ja) | 2010-10-05 | 2012-04-12 | 国立大学法人大阪大学 | ヘルパーt細胞の活性化方法 |
WO2014042226A1 (ja) | 2012-09-12 | 2014-03-20 | 株式会社癌免疫研究所 | 抗原特異的ヘルパーt細胞レセプター遺伝子 |
WO2014098012A1 (ja) | 2012-12-17 | 2014-06-26 | 大塚製薬株式会社 | ヘルパーt細胞の活性化方法 |
EP2762160A1 (en) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | Wt1 peptide cancer vaccine composition for mucosal administration |
EP2762156A1 (en) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | Tape preparation of WT1 peptide cancer vaccine for transdermal administration |
EP2762155A2 (en) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | Vaccine Composition |
EP2762152A1 (en) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | WT1 peptide cancer vaccine composition for transdermal administration |
EP2762157A1 (en) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | Vaccine composition for transdermal or mucosal administration |
EP2762153A2 (en) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | Vaccine composition for mucosal administration |
EP2762154A2 (en) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | Vaccine composition for transdermal administration |
EP2762159A1 (en) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | WT1 peptide cancer vaccine composition for transdermal administration |
WO2016093326A1 (ja) * | 2014-12-11 | 2016-06-16 | 株式会社癌免疫研究所 | 血管新生病の免疫療法 |
WO2018088439A1 (ja) | 2016-11-09 | 2018-05-17 | 国立大学法人大阪大学 | T細胞集団の改変方法 |
US10124046B2 (en) | 2003-11-05 | 2018-11-13 | International Institute Of Cancer Immunology, Inc. | HLA-DR-binding antigen peptide derived from WT1 |
US10947503B2 (en) | 2014-12-25 | 2021-03-16 | International Institute Of Cancer Immunology, Inc. | Method for modifying T cell population |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2900087C (en) | 2005-10-17 | 2024-02-13 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
AU2007218649B2 (en) | 2006-02-22 | 2013-01-10 | International Institute Of Cancer Immunology, Inc. | HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same |
US9265816B2 (en) | 2006-04-10 | 2016-02-23 | Sloan Kettering Institute For Cancer Research | Immunogenic WT-1 peptides and methods of use thereof |
ES2785081T3 (es) | 2011-04-01 | 2020-10-05 | Memorial Sloan Kettering Cancer Center | Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2 |
EP2757373A4 (en) * | 2011-09-14 | 2015-07-01 | Int Inst Cancer Immunology Inc | METHOD FOR MEASURING ANTI-WT1 ANTIBODIES |
WO2013106834A2 (en) | 2012-01-13 | 2013-07-18 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
MX364732B (es) * | 2012-12-13 | 2019-05-06 | Univ Pennsylvania | Vacuna contra el tumor de wilms 1. |
LT2945647T (lt) | 2013-01-15 | 2021-02-25 | Memorial Sloan Kettering Cancer Center | Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai |
US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
JP2018513128A (ja) | 2015-03-20 | 2018-05-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Isg15及びアジュバントとしてのその使用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000018795A2 (en) * | 1998-09-30 | 2000-04-06 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
WO2001025273A2 (en) * | 1999-10-04 | 2001-04-12 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
WO2002028414A1 (en) * | 2000-10-06 | 2002-04-11 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
WO2003037060A2 (en) * | 2001-10-30 | 2003-05-08 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
WO2003106682A1 (ja) | 2002-06-12 | 2003-12-24 | 中外製薬株式会社 | Hla−a24拘束性癌抗原ペプチド |
WO2005095598A1 (ja) | 2004-03-31 | 2005-10-13 | International Institute Of Cancer Immunology, Inc. | Wt1由来の癌抗原ペプチド |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3393867B2 (ja) | 1989-11-13 | 2003-04-07 | マサチユーセツツ・インステイテユート・オブ・テクノロジー | ウィルムス腫瘍遺伝子の位置決定と特徴付け |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US6344436B1 (en) * | 1996-01-08 | 2002-02-05 | Baylor College Of Medicine | Lipophilic peptides for macromolecule delivery |
US6270777B1 (en) * | 1996-12-20 | 2001-08-07 | University Technologies International Inc. | Conserved metalloprotease epitopes |
GB9805877D0 (en) * | 1998-03-20 | 1998-05-13 | Imp Cancer Res Tech | Cancer |
US7063854B1 (en) | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
US7655249B2 (en) | 1998-09-30 | 2010-02-02 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7901693B2 (en) | 1998-09-30 | 2011-03-08 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US20030039635A1 (en) | 1998-09-30 | 2003-02-27 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7144581B2 (en) | 2000-10-09 | 2006-12-05 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7115272B1 (en) | 1998-09-30 | 2006-10-03 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US6797695B1 (en) * | 1999-10-22 | 2004-09-28 | Kyoto University | Human FGF-20 gene and gene expression products |
AU2001285018A1 (en) * | 2000-08-17 | 2002-02-25 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer |
ATE383375T1 (de) * | 2001-03-22 | 2008-01-15 | Int Inst Cancer Immunology Inc | Wti-modifiziertes peptid |
US20040197892A1 (en) * | 2001-04-04 | 2004-10-07 | Michael Moore | Composition binding polypeptides |
SI20875A (sl) * | 2001-04-25 | 2002-10-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Kristalna oblika omeprazola |
AU2003262094A1 (en) * | 2002-09-12 | 2004-04-30 | Haruo Sugiyama | Cancer antigen peptide preparation |
ES2332590T3 (es) | 2003-01-15 | 2010-02-09 | International Institute Of Cancer Immunology, Inc. | Dimero peptidico. |
WO2004067716A2 (en) * | 2003-01-24 | 2004-08-12 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer |
US6980709B2 (en) | 2003-06-20 | 2005-12-27 | Northrop Grumman Corporation | Polymeric material with voids that compress to allow the polymeric material to absorb applied force and decrease reaction force to one or more sensor fibers |
AU2007218649B2 (en) | 2006-02-22 | 2013-01-10 | International Institute Of Cancer Immunology, Inc. | HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same |
-
2007
- 2007-02-21 AU AU2007218649A patent/AU2007218649B2/en not_active Ceased
- 2007-02-21 MY MYPI20082861A patent/MY149527A/en unknown
- 2007-02-21 CN CN2011101569270A patent/CN102250211A/zh active Pending
- 2007-02-21 CN CN2007800059709A patent/CN101384716B/zh active Active
- 2007-02-21 PL PL07714676T patent/PL1988163T3/pl unknown
- 2007-02-21 PT PT07714676T patent/PT1988163E/pt unknown
- 2007-02-21 MX MX2008010842A patent/MX2008010842A/es active IP Right Grant
- 2007-02-21 ES ES12174393.4T patent/ES2558330T3/es active Active
- 2007-02-21 EP EP11161436.8A patent/EP2385117B1/en not_active Not-in-force
- 2007-02-21 US US12/280,268 patent/US8759483B2/en not_active Expired - Fee Related
- 2007-02-21 RU RU2008137635/10A patent/RU2435782C2/ru not_active IP Right Cessation
- 2007-02-21 ES ES11161436.8T patent/ES2587980T3/es active Active
- 2007-02-21 DK DK07714676.9T patent/DK1988163T3/da active
- 2007-02-21 SI SI200730972T patent/SI1988163T1/sl unknown
- 2007-02-21 CA CA2886615A patent/CA2886615A1/en not_active Abandoned
- 2007-02-21 EP EP07714676A patent/EP1988163B1/en not_active Not-in-force
- 2007-02-21 CA CA2886552A patent/CA2886552A1/en not_active Abandoned
- 2007-02-21 JP JP2008501735A patent/JP5393144B2/ja active Active
- 2007-02-21 EP EP12174393.4A patent/EP2518149B1/en not_active Not-in-force
- 2007-02-21 WO PCT/JP2007/053176 patent/WO2007097358A1/ja active Application Filing
- 2007-02-21 BR BRPI0708125-1A patent/BRPI0708125A2/pt not_active IP Right Cessation
- 2007-02-21 CA CA002638122A patent/CA2638122A1/en not_active Abandoned
- 2007-02-21 CN CN201210158264.0A patent/CN102702319B/zh not_active Expired - Fee Related
- 2007-02-21 ES ES07714676T patent/ES2387685T3/es active Active
- 2007-02-21 CA CA2886551A patent/CA2886551A1/en not_active Abandoned
- 2007-02-21 DK DK12174393.4T patent/DK2518149T3/en active
-
2008
- 2008-07-24 IL IL193026A patent/IL193026A/en not_active IP Right Cessation
- 2008-07-28 ZA ZA200806542A patent/ZA200806542B/xx unknown
- 2008-08-21 KR KR1020087020447A patent/KR101391561B1/ko active IP Right Grant
- 2008-09-19 NO NO20084008A patent/NO20084008L/no not_active Application Discontinuation
-
2009
- 2009-04-28 HK HK09103920.0A patent/HK1125968A1/xx unknown
-
2011
- 2011-07-29 RU RU2011132212/10A patent/RU2011132212A/ru not_active Application Discontinuation
-
2012
- 2012-02-16 IL IL218172A patent/IL218172A0/en unknown
- 2012-03-02 US US13/411,453 patent/US8778350B2/en not_active Expired - Fee Related
- 2012-09-18 CY CY20121100848T patent/CY1113117T1/el unknown
- 2012-11-29 PH PH12012502372A patent/PH12012502372A1/en unknown
-
2013
- 2013-12-31 US US14/145,221 patent/US8933038B2/en not_active Expired - Fee Related
- 2013-12-31 US US14/145,363 patent/US8945578B2/en not_active Expired - Fee Related
- 2013-12-31 US US14/145,144 patent/US8968745B2/en not_active Expired - Fee Related
-
2014
- 2014-05-01 IL IL232408A patent/IL232408A0/en unknown
- 2014-05-01 IL IL232409A patent/IL232409A0/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000018795A2 (en) * | 1998-09-30 | 2000-04-06 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
WO2001025273A2 (en) * | 1999-10-04 | 2001-04-12 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
WO2002028414A1 (en) * | 2000-10-06 | 2002-04-11 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
WO2003037060A2 (en) * | 2001-10-30 | 2003-05-08 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
WO2003106682A1 (ja) | 2002-06-12 | 2003-12-24 | 中外製薬株式会社 | Hla−a24拘束性癌抗原ペプチド |
WO2005095598A1 (ja) | 2004-03-31 | 2005-10-13 | International Institute Of Cancer Immunology, Inc. | Wt1由来の癌抗原ペプチド |
Non-Patent Citations (19)
Title |
---|
"Peptide Synthesis", 1966, INTERSCIENCE |
"Peptide-Gosei No Kiso To Jikken", 1985, MARUZEN CO., LTD. |
"Peptide-Gosei", 1975, MARUZEN CO., LTD. |
"Peptide-Gosei", vol. 14, 1991, HIROKAWA - BOOK, article "Iyakuhin No Kaihatsu (Zoku)" |
"The Proteins", vol. 2, 1976, ACADEMIC PRESS INC. |
CALL KM ET AL., CELL, vol. 60, no. 3, 9 February 1990 (1990-02-09), pages 509 - 20 |
DANIEL A. HABER ET AL., CELL, vol. 61, no. 7, 29 June 1990 (1990-06-29), pages 1257 - 69 |
GAO L ET AL., BLOOD., vol. 95, no. 7, 1 April 2000 (2000-04-01), pages 2198 - 203 |
INOUE K ET AL., BLOOD, vol. 91, no. 8, 15 April 1998 (1998-04-15), pages 2969 - 76 |
MELIEF CJ ET AL., IMMUNOL REV., vol. 145, June 1995 (1995-06-01), pages 167 - 77 |
MENKE AL ET AL., INT REV CYTOL., vol. 181, 1998, pages 151 - 212 |
OHMINAMI H ET AL., BLOOD, vol. 95, no. 1, 1 January 2000 (2000-01-01), pages 286 - 93 |
OKA Y ET AL., IMMUNOGENETICS, vol. 51, no. 2, February 2000 (2000-02-01), pages 99 - 107 |
OKA Y ET AL., J IMMUNOL., vol. 164, no. 4, 15 February 2000 (2000-02-15), pages 1873 - 80 |
RITZ J, J CLIN ONCOL., vol. 12, no. 2, February 1994 (1994-02-01), pages 237 - 8 |
See also references of EP1988163A4 |
TSUBOI A ET AL., J CLIN IMMUNOL., vol. 20, no. 3, May 2000 (2000-05-01), pages 195 - 202 |
TSUBOI A ET AL., LEUK RES., vol. 23, no. 5, May 1999 (1999-05-01), pages 499 - 505 |
YAMAGAMI T ET AL., BLOOD, vol. 87, no. 7, 1 April 1996 (1996-04-01), pages 2878 - 84 |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11027003B2 (en) | 2003-11-05 | 2021-06-08 | International Institute Of Cancer Immunology, Inc. | HLA-DR-binding antigen peptide derived from WT1 |
US10124046B2 (en) | 2003-11-05 | 2018-11-13 | International Institute Of Cancer Immunology, Inc. | HLA-DR-binding antigen peptide derived from WT1 |
WO2008105462A1 (ja) | 2007-02-27 | 2008-09-04 | International Institute Of Cancer Immunology, Inc. | ヘルパーt細胞の活性化方法およびそのための組成物 |
US11555814B2 (en) | 2007-02-27 | 2023-01-17 | International Institute Of Cancer Immunology, Inc. | Method for activation of helper t cell and composition for use in the method |
US10139395B2 (en) | 2007-02-27 | 2018-11-27 | International Institute Of Cancer Immunology, Inc. | Method for activation of helper T cell and composition for use in the method |
US10654892B2 (en) | 2010-10-05 | 2020-05-19 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
KR20190034359A (ko) | 2010-10-05 | 2019-04-01 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 헬퍼 t 세포의 활성화 방법 |
KR20200018738A (ko) | 2010-10-05 | 2020-02-19 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 헬퍼 t 세포의 활성화 방법 |
WO2012046730A1 (ja) | 2010-10-05 | 2012-04-12 | 国立大学法人大阪大学 | ヘルパーt細胞の活性化方法 |
WO2014042226A1 (ja) | 2012-09-12 | 2014-03-20 | 株式会社癌免疫研究所 | 抗原特異的ヘルパーt細胞レセプター遺伝子 |
US10815288B2 (en) | 2012-09-12 | 2020-10-27 | International Institute Of Cancer Immunology, Inc. | Antigen-specific helper T-cell receptor genes |
EP3495483A1 (en) | 2012-09-12 | 2019-06-12 | International Institute of Cancer Immunology, Inc. | Antigen-specific helper t-cell receptor genes |
US20160009781A1 (en) | 2012-09-12 | 2016-01-14 | International Institute Of Cancer Immunology, Inc. | Antigen-specific helper t-cell receptor genes |
US11091531B2 (en) | 2012-09-12 | 2021-08-17 | International Institute Of Cancer Immunology, Inc. | Antigen-specific helper T-cell receptor genes |
KR20150096697A (ko) | 2012-12-17 | 2015-08-25 | 오츠카 세이야쿠 가부시키가이샤 | 헬퍼 t세포의 활성화 방법 |
WO2014098012A1 (ja) | 2012-12-17 | 2014-06-26 | 大塚製薬株式会社 | ヘルパーt細胞の活性化方法 |
US9833493B2 (en) | 2012-12-17 | 2017-12-05 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
EP2762157A1 (en) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | Vaccine composition for transdermal or mucosal administration |
EP2762155A2 (en) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | Vaccine Composition |
EP2762160A1 (en) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | Wt1 peptide cancer vaccine composition for mucosal administration |
EP2762156A1 (en) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | Tape preparation of WT1 peptide cancer vaccine for transdermal administration |
EP2762159A1 (en) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | WT1 peptide cancer vaccine composition for transdermal administration |
EP2762152A1 (en) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | WT1 peptide cancer vaccine composition for transdermal administration |
EP2762154A2 (en) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | Vaccine composition for transdermal administration |
EP3662927A2 (en) | 2013-02-05 | 2020-06-10 | Nitto Denko Corporation | Vaccine composition |
EP2762153A2 (en) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | Vaccine composition for mucosal administration |
AU2015362379B2 (en) * | 2014-12-11 | 2020-05-14 | International Institute Of Cancer Immunology, Inc. | Immunotherapy for angiogenic disease |
US10525096B2 (en) | 2014-12-11 | 2020-01-07 | International Institute Of Cancer Immunology, Inc. | Immunotherapy for angiogenic disease |
WO2016093326A1 (ja) * | 2014-12-11 | 2016-06-16 | 株式会社癌免疫研究所 | 血管新生病の免疫療法 |
US11369656B2 (en) | 2014-12-11 | 2022-06-28 | International Institute Of Cancer Immunology, Inc. | Immunotherapy for angiogenic disease |
US11413322B2 (en) | 2014-12-11 | 2022-08-16 | International Institute Of Cancer Immunology, Inc. | Immunotherapy for angiogenic disease |
JPWO2016093326A1 (ja) * | 2014-12-11 | 2017-09-14 | 株式会社癌免疫研究所 | 血管新生病の免疫療法 |
US10947503B2 (en) | 2014-12-25 | 2021-03-16 | International Institute Of Cancer Immunology, Inc. | Method for modifying T cell population |
US10899790B2 (en) | 2016-11-09 | 2021-01-26 | Osaka University | Method for modifying T cell population |
WO2018088439A1 (ja) | 2016-11-09 | 2018-05-17 | 国立大学法人大阪大学 | T細胞集団の改変方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5393144B2 (ja) | Hla−a*3303拘束性wt1ペプチド、およびそれを含む医薬組成物 | |
JP5484734B2 (ja) | Hla−a*1101拘束性wt1ペプチド、およびそれを含む医薬組成物 | |
JP4365405B2 (ja) | Mhc分子と結合する腫瘍関連ペプチド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2638122 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 193026 Country of ref document: IL Ref document number: 2007714676 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007218649 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008081345 Country of ref document: EG |
|
ENP | Entry into the national phase |
Ref document number: 2008501735 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008501853 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4345/CHENP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780005970.9 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2007218649 Country of ref document: AU Date of ref document: 20070221 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/010842 Country of ref document: MX Ref document number: 1020087020447 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2008137635 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12280268 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0708125 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080821 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 218172 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 232408 Country of ref document: IL Ref document number: 232409 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201504880 Country of ref document: ID |